Bioventix Balance Sheet Health
Financial Health criteria checks 6/6
Bioventix has a total shareholder equity of £12.0M and total debt of £0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are £13.7M and £1.7M respectively. Bioventix's EBIT is £10.6M making its interest coverage ratio -52.6. It has cash and short-term investments of £6.0M.
Key information
0%
Debt to equity ratio
UK£0
Debt
| Interest coverage ratio | -52.6x |
| Cash | UK£6.00m |
| Equity | UK£12.00m |
| Total liabilities | UK£1.73m |
| Total assets | UK£13.73m |
Recent financial health updates
Recent updates
Estimating The Fair Value Of Bioventix PLC (LON:BVXP)
Jun 19
Bioventix's (LON:BVXP) Dividend Will Be £0.68
Mar 29We Think Shareholders May Consider Being More Generous With Bioventix PLC's (LON:BVXP) CEO Compensation Package
Dec 01Bioventix (LON:BVXP) Is Increasing Its Dividend To £0.62
Mar 30Bioventix (LON:BVXP) Is Increasing Its Dividend To UK£0.52
Mar 31Should Bioventix PLC (LON:BVXP) Be Part Of Your Dividend Portfolio?
Mar 29Is Now The Time To Put Bioventix (LON:BVXP) On Your Watchlist?
Mar 14What Does Bioventix's (LON:BVXP) CEO Pay Reveal?
Feb 27Shareholders of Bioventix (LON:BVXP) Must Be Delighted With Their 364% Total Return
Jan 31Is Bioventix PLC (LON:BVXP) Popular Amongst Insiders?
Jan 18
Is Bioventix PLC's (LON:BVXP) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 06Here's How We Evaluate Bioventix PLC's (LON:BVXP) Dividend
Dec 23Does Bioventix's (LON:BVXP) CEO Salary Compare Well With Industry Peers?
Nov 28Financial Position Analysis
Short Term Liabilities: BVXP's short term assets (£12.8M) exceed its short term liabilities (£1.7M).
Long Term Liabilities: BVXP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BVXP is debt free.
Reducing Debt: BVXP has not had any debt for past 5 years.
Debt Coverage: BVXP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BVXP has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 22:09 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioventix PLC is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Buxton | Cavendish |
| null null | Cavendish |
| Adam McCarter | Cavendish |